According to filings with the U.S. Securities and Exchange Commission, Transition Bio is raising up to $21,265,426.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Transition Bio
Transition Bio is developing one-of-a-kind technologies for biomolecular condensate analysis. Through our Condensomics platform, our goal is to build a drug discovery engine based on the latest advancements in biophysics and artificial intelligence. We harness droplet microfluidic approaches and cellular platforms to characterize condensates with unprecedented scale and precision, resulting in the mapping of condensates and their modulation, in molecular detail. Our proprietary datasets feed in to algorithms that we use for target discovery, target validation and drug design.

To learn more about Transition Bio, visit http://www.transitionbio.com/
Transition Bio Linkedin Page: https://www.linkedin.com/company/transition-bio-inc/

Contact:
Samuel Cohen, Co-Founder
917-445-5573
https://www.linkedin.com/in/samuel-cohen-3b301816/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.